Magayr Tajdida A, Song Xuewen, Streets Andrew J, Vergoz Laura, Chang Lijun, Valluru Manoj K, Yap Hsiu L, Lannoy Morgane, Haghighi Amirreza, Simms Roslyn J, Tam Frederick W K, Pei York, Ong Albert C M
Kidney Genetics Group, Academic Nephrology Unit, University of Sheffield Medical School, Sheffield, UK.
Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Kidney Int. 2020 Aug;98(2):420-435. doi: 10.1016/j.kint.2020.02.008. Epub 2020 Mar 6.
MicroRNAs (miRNAs) play an important role in regulating gene expression in health and disease but their role in modifying disease expression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) remains uncertain. Here, we profiled human urinary exosome miRNA by global small RNA-sequencing in an initial discovery cohort of seven patients with ADPKD with early disease (eGFR over 60ml/min/1.73m), nine with late disease (eGFR under 60ml/min/1.73m), and compared their differential expression with six age and sex matched healthy controls. Two kidney-enriched candidate miRNA families were identified (miR-192/miR-194-2 and miR-30) and selected for confirmatory testing in a 60 patient validation cohort by quantitative polymerase chain reaction. We confirmed that miR-192-5p, miR-194-5p, miR-30a-5p, miR-30d-5p and miR-30e-5p were significantly downregulated in patient urine exosomes, in murine Pkd1 cystic kidneys and in human PKD1 cystic kidney tissue. All five miRNAs showed significant correlations with baseline eGFR and ultrasound-determined mean kidney length and improved the diagnostic performance (area under the curve) of mean kidney length for the rate of disease progression. Finally, inverse correlations of these two miRNA families with increased expression in their predicted target genes in patient PKD1 cystic tissue identified dysregulated pathways and transcriptional networks including novel interactions between miR-194-5p and two potentially relevant candidate genes, PIK3R1 and ANO1. Thus, our results identify a subset of urinary exosomal miRNAs that could serve as novel biomarkers of disease progression and suggest new therapeutic targets in ADPKD.
微小RNA(miRNA)在健康和疾病状态下的基因表达调控中发挥着重要作用,但其在常染色体显性多囊肾病(ADPKD)疾病表达修饰中的作用仍不明确。在此,我们通过对7例早期疾病(估算肾小球滤过率(eGFR)超过60ml/min/1.73m²)的ADPKD患者、9例晚期疾病(eGFR低于60ml/min/1.73m²)的ADPKD患者以及6例年龄和性别匹配的健康对照进行全基因组小RNA测序,分析了人类尿液外泌体miRNA。我们鉴定出两个肾脏富集的候选miRNA家族(miR-192/miR-194-2和miR-30),并通过定量聚合酶链反应在60例患者的验证队列中进行了确证性检测。我们证实,miR-192-5p、miR-194-5p、miR-30a-5p、miR-30d-5p和miR-30e-5p在患者尿液外泌体、小鼠Pkd1囊性肾以及人类PKD1囊性肾组织中均显著下调。所有这五种miRNA均与基线eGFR和超声测定的平均肾长显著相关,并改善了平均肾长对疾病进展率的诊断性能(曲线下面积)。最后,这两个miRNA家族与患者PKD1囊性组织中预测靶基因表达增加呈负相关,确定了失调的信号通路和转录网络,包括miR-194-5p与两个潜在相关候选基因PIK3R1和ANO1之间的新型相互作用。因此,我们的研究结果鉴定出了一组尿液外泌体miRNA,它们可能作为疾病进展的新型生物标志物,并提示了ADPKD新的治疗靶点。